Ingredion Incorporated Just Recorded A 8.0% Earnings Beat: Here's What Analysts Think

As you might know, Ingredion Incorporated (NYSE:INGR) just kicked off its latest full-year results with some very strong numbers. Results were good overall, with revenues beating analyst predictions by 8.0% to hit US$6.2b. Statutory earnings per share (EPS) came in at US$6.13, some 2.5% above what analysts had expected. This is an important time for investors, as they can track a company's performance in its report, look at what top analysts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

Check out our latest analysis for Ingredion

NYSE:INGR Past and Future Earnings, February 14th 2020
NYSE:INGR Past and Future Earnings, February 14th 2020

Following last week's earnings report, Ingredion's six analysts are forecasting 2020 revenues to be US$6.18b, approximately in line with the last 12 months. Statutory earnings per share are expected to ascend 12% to US$6.92. Before this earnings report, analysts had been forecasting revenues of US$5.85b and earnings per share (EPS) of US$7.08 in 2020. So it's pretty clear consensus is mixed on Ingredion after the latest results; while analysts lifted revenue numbers, they also administered a small dip in per-share earnings expectations.

Analysts also upgraded Ingredion's price target 5.6% to US$103, implying that the higher sales are expected to generate enough value to offset the forecast decline in earnings. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Ingredion, with the most bullish analyst valuing it at US$125 and the most bearish at US$79.00 per share. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

In addition, we can look to Ingredion's past performance and see whether business is expected to improve, and if the company is expected to perform better than wider market. We would highlight that sales are expected to reverse, with the forecast 0.4% revenue decline a notable change from historical growth of 1.1% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same market are forecast to see their revenue grow 2.7% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - analysts also expect Ingredion to grow slower than the wider market.

Advertisement

The Bottom Line

The most important thing to take away is that analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Fortunately, analysts also upgraded their revenue estimates, although our data indicates sales are expected to perform worse than the wider market. There was also a nice increase in the price target, with analysts feeling that the intrinsic value of the business is improving.

Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. At Simply Wall St, we have a full range of analyst estimates for Ingredion going out to 2022, and you can see them free on our platform here..

It might also be worth considering whether Ingredion's debt load is appropriate, using our debt analysis tools on the Simply Wall St platform, here.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

About NYSE:INGR

Ingredion

Engages in the manufacture and sale of sweeteners, starches, nutrition ingredients, and biomaterial solutions derived from wet milling and processing corn, and other starch-based materials to a range of industries worldwide.

Very undervalued with flawless balance sheet and pays a dividend.

Advertisement

Weekly Picks

LO
Lou_Basenese
VTIX logo
Lou_Basenese on Virtuix Holdings ·

From a “Shark Tank” Snub to an Air Force “Yes”: Why Virtuix at $3.50 May Be the Market’s Most Mispriced AI Story

Fair Value:US$7.558.3% undervalued
16 users have followed this narrative
0 users have commented on this narrative
2 users have liked this narrative
IN
Investingwilly
MA logo
Investingwilly on Mastercard ·

Mastercard: The Best Dividend Stock You're Ignoring

Fair Value:US$75034.8% undervalued
61 users have followed this narrative
1 users have commented on this narrative
7 users have liked this narrative
TR
tripledub
INTU logo
tripledub on Intuit ·

A Wonderful Business at a Not-So-Wonderful Price

Fair Value:US$56054.5% undervalued
60 users have followed this narrative
4 users have commented on this narrative
29 users have liked this narrative
TA
Talos
HYFT logo
Talos on MindWalk Holdings ·

The Asymmetric TechBio Play: MindWalk Holdings and the Valuation Disconnect

Fair Value:US$8.2781.6% undervalued
33 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative

Updated Narratives

GA
PLTR logo
GaryB on Palantir Technologies ·

Palantir hits 52 week low.

Fair Value:US$274.861.0% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
NO
EWY logo
North49_ on iShares - iShares MSCI South Korea ETF ·

EWY:US NYSE Arca iShares Msci South Korea ETF, an opportunity to diversify your tech investments.

Fair Value:US$273.4525.0% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.884.9% undervalued
89 users have followed this narrative
7 users have commented on this narrative
1 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7445.2% undervalued
67 users have followed this narrative
0 users have commented on this narrative
16 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$319.9639.6% undervalued
61 users have followed this narrative
9 users have commented on this narrative
18 users have liked this narrative
HE
HedgeY
ASTS logo
HedgeY on AST SpaceMobile ·

AST SpaceMobile: The Boldest Direct-to-Cell Bet in Public Markets

Fair Value:US$17061.4% undervalued
51 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative